Igor Makhlin

8PUBLICATIONS
41CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 02, 2025
Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial.

Angela DeMichele, Amy S Clark, Emily Shea

|Aug 27, 2024
Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights.

Igor Makhlin, Lesley Fallowfield, N Lynn Henry

|Apr 04, 2024
Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial.

Igor Makhlin, Biniyam G Demissei, Ralph D'Agostino

|Jun 10, 2023
Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer.

Michael G Fradley, Nam H K Nguyen, David Madnick

|Nov 12, 2022
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer.

Igor Makhlin, Nicholas P McAndrew, E Paul Wileyto

|Oct 21, 2022
<sup>18</sup>F-FDG PET/CT for the Evaluation of Therapy Response in Hormone Receptor-Positive Bone-Dominant Metastatic Breast Cancer.

Igor Makhlin, Katrina Esther Korhonen, Melissa Lynne Martin

Pageof 2

Frequent Collaborators

5 joint publications

Angela DeMichele

3 joint publications

Amy S Clark

2 joint publications

Bonnie Ky

1 joint publications

Stephen J Bagley